RT Journal Article SR Electronic T1 Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.28.20163378 DO 10.1101/2020.07.28.20163378 A1 Martina McMenamin A1 Michael J Grayling A1 Anna Berglind A1 James MS Wason YR 2020 UL http://medrxiv.org/content/early/2020/07/29/2020.07.28.20163378.abstract AB Background Composite responder endpoints feature frequently in rheumatology due to the multifaceted nature of many of these conditions. Current analysis methods used to analyse these endpoints discard much of the data used to classify patients as responders; they are therefore highly inefficient and result in low power.Methods We highlight a novel augmented methodology that uses more of the information available to improve the precision of reported treatment effects. Since these methods are more challenging to implement, we have developed free, user friendly software available in a web-based interface. The software consists of two programs: one that supports the analysis of responder endpoints; the second is used for sample size estimation. We demonstrate the augmented analysis method and its software using the MUSE study, a phase IIb trial in patients with systemic lupus erythematosus.Results We show the software can be used to analyse the trial with efficiency gains translating to a reduction in required sample size of 63%. Furthermore, we illustrate how the software can be used to choose the sample size needed in a future trial that will use the novel approach as the primary analysis method.Conclusion We encourage trialists to utilise the software we have developed to implement augmented methodology in future studies to improve efficiency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by NIHR Cambridge Biomedical Research Centre (BRC). The funding body did not have a role in the design of the study, analysis, interpretation of data or writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors do not own the trial data used in the manuscript to illustrate the software, so we are unable to make it available.